Last week, the Food and Drug Administration (FDA) released a “Drug Safety Communication,” warning that Veozah (fezolinetant), a new medicine to treat hot flashes due to menopause, can cause ...

US drugs watchdog the FDA has placed its most serious warning - called a black box warning - on the non-hormonal drug fezolinetant, which is sold under the brand name Veozah and developed by ...

The once-daily oral drug has been cleared under the Veozah brand name for moderate to severe vasomotor symptoms (commonly known as hot flashes) in menopausal women, becoming a non-hormonal ...

The company hasn’t given a timeline for those regulatory filings but will no doubt want to move quickly as it chases after Astellas, which claimed approval for NK 3 antagonist Veozah ...